News Chart Nektar Therapeutics

Equities

NKTR

US6402681083

Real-time Estimate Cboe BZX Other stock markets 01:40:09 2024-05-09 pm EDT			5-day change	1st Jan Change
1.655 ^USD	+0.91%		-0.90%	+192.92%

Apr. 24	Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	CI
Mar. 19	Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	CI

473e050b059e709221f06fb30fe.uvfA2gEmz36_Lg5URW3bTJysnHJOY_x2lvGsSL8vaNM.96L2imtH9hyOVmU4AB-TesrnxCYHNJRGrtzFBfEWDIn8v_icUWT8SOVePg~0cfc1d888f4c91b80b7a8da6c61d0bbe